Company profile ORTX

Orchard Therapeutics plc
orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and... commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world. Show More
Quarter analysis & expected interest

There is not enough data for Orchard Therapeutics gene therapy to provide analysis

Correlation between past revenue and Orchard Therapeutics gene therapy search interest

There is not enough data for Orchard Therapeutics gene therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Orchard Therapeutics gene therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Libmeldy gene therapy to provide analysis

Correlation between past revenue and Libmeldy gene therapy search interest

There is not enough data for Libmeldy gene therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Libmeldy gene therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Strimvelis gene therapy to provide analysis

Correlation between past revenue and Strimvelis gene therapy search interest

There is not enough data for Strimvelis gene therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Strimvelis gene therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTL-200 to provide analysis

Correlation between past revenue and OTL-200 search interest

There is not enough data for OTL-200 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTL-200 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTL-203 to provide analysis

Correlation between past revenue and OTL-203 search interest

There is not enough data for OTL-203 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTL-203 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTL-201 to provide analysis

Correlation between past revenue and OTL-201 search interest

There is not enough data for OTL-201 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTL-201 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OTL-204 to provide analysis

Correlation between past revenue and OTL-204 search interest

There is not enough data for OTL-204 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OTL-204 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 04:22:10.

After 39 days of this quarter the interest is at 34.0. Based on that we can calculate that during remaining 52 days it will total up to 79.0.
metachromatic leukodystrophy expected interest is significantly lower compared to previous quarter (-81.0%) and same quarter last year (-84.7%).

YearQ1Q2Q3Q4
2019288
404
40.3% QoQ
218
-46.0% QoQ
358
64.2% QoQ
2020 395
37.2% YoY 10.3% QoQ
294
-27.2% YoY -25.6% QoQ
373
71.1% YoY 26.9% QoQ
303
-15.4% YoY -18.8% QoQ
2021 368
-6.8% YoY 21.5% QoQ
344
17.0% YoY -6.5% QoQ
400
7.2% YoY 16.3% QoQ
294
-3.0% YoY -26.5% QoQ
2022 420
14.1% YoY 42.9% QoQ
433
25.9% YoY 3.1% QoQ
381
-4.8% YoY -12.0% QoQ
412
40.1% YoY 8.1% QoQ
2023 515
22.6% YoY 25.0% QoQ
392
-9.5% YoY -23.9% QoQ
340
-10.8% YoY -13.3% QoQ
415
0.7% YoY 22.1% QoQ
2024 34
-93.4% YoY -91.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and metachromatic leukodystrophy search interestLast update: February 09 2024 04:22:08.
Correlation coefficient between keyword and revenue is 0.11
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 04:22:13.

The average 5 years interest of metachromatic leukodystrophy was 28.28 per week.
The last year interest of metachromatic leukodystrophy compared to the last 5 years has changed by 3.36%.
The interest for metachromatic leukodystrophy is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 5.91%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 06 2023 05:48:29.

After 34 days of this quarter the interest is at 79.0. Based on that we can calculate that during remaining 58 days it will total up to 214.0.
adenosine deaminase deficiency expected interest is significantly higher compared to previous quarter (+289.1%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 89
2019 261
193.3% QoQ
108
-58.6% QoQ
140
29.6% QoQ
267
200.0% YoY 90.7% QoQ
2020 161
-38.3% YoY -39.7% QoQ
139
28.7% YoY -13.7% QoQ
171
22.1% YoY 23.0% QoQ
76
-71.5% YoY -55.6% QoQ
2021 137
-14.9% YoY 80.3% QoQ
82
-41.0% YoY -40.1% QoQ
100
-41.5% YoY 22.0% QoQ
174
128.9% YoY 74.0% QoQ
2022 296
116.1% YoY 70.1% QoQ
243
196.3% YoY -17.9% QoQ
113
13.0% YoY -53.5% QoQ
181
4.0% YoY 60.2% QoQ
2023 104
-64.9% YoY -42.5% QoQ
218
-10.3% YoY 109.6% QoQ
55
-51.3% YoY -74.8% QoQ
79
-56.4% YoY 43.6% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and adenosine deaminase deficiency search interestLast update: November 06 2023 05:48:29.
Correlation coefficient between keyword and revenue is 0.23
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 06 2023 05:48:30.

The average 5 years interest of adenosine deaminase deficiency was 12.28 per week.
The last year interest of adenosine deaminase deficiency compared to the last 5 years has changed by -10.42%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -25.22%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for mucopolysaccharidosis type I to provide analysis

Correlation between past revenue and mucopolysaccharidosis type I search interest

There is not enough data for mucopolysaccharidosis type I to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for mucopolysaccharidosis type I to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for mucopolysaccharidosis type IIIA to provide analysis

Correlation between past revenue and mucopolysaccharidosis type IIIA search interest

There is not enough data for mucopolysaccharidosis type IIIA to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for mucopolysaccharidosis type IIIA to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for frontotemporal dementia with progranulin mutations to provide analysis

Correlation between past revenue and frontotemporal dementia with progranulin mutations search interest

There is not enough data for frontotemporal dementia with progranulin mutations to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for frontotemporal dementia with progranulin mutations to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Crohn's disease with mutations to provide analysis

Correlation between past revenue and Crohn's disease with mutations search interest

There is not enough data for Crohn's disease with mutations to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Crohn's disease with mutations to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 04:22:22.

After 39 days of this quarter the interest is at 86.0. Based on that we can calculate that during remaining 52 days it will total up to 201.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019134
212
58.2% QoQ
256
20.8% QoQ
202
-21.1% QoQ
2020 203
51.5% YoY 0.5% QoQ
194
-8.5% YoY -4.4% QoQ
197
-23.0% YoY 1.5% QoQ
189
-6.4% YoY -4.1% QoQ
2021 202
-0.5% YoY 6.9% QoQ
176
-9.3% YoY -12.9% QoQ
191
-3.0% YoY 8.5% QoQ
180
-4.8% YoY -5.8% QoQ
2022 416
105.9% YoY 131.1% QoQ
270
53.4% YoY -35.1% QoQ
402
110.5% YoY 48.9% QoQ
288
60.0% YoY -28.4% QoQ
2023 233
-44.0% YoY -19.1% QoQ
317
17.4% YoY 36.1% QoQ
259
-35.6% YoY -18.3% QoQ
213
-26.0% YoY -17.8% QoQ
2024 86
-63.1% YoY -59.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and hereditary angioedema search interestLast update: February 09 2024 04:22:21.
Correlation coefficient between keyword and revenue is 0.43
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 04:22:25.

The average 5 years interest of hereditary angioedema was 18.47 per week.
The last year interest of hereditary angioedema compared to the last 5 years has changed by 4.22%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 11.72%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ORTX
Earnings date: 2024-03-05 After close
Company name: Orchard Therapeutics plc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2024-05-07T11:00:17Z

GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

2024-05-03T11:00:38Z

GlobeNewswire
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

2024-03-20T11:00:07Z

GlobeNewswire
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

2024-03-18T19:41:13Z

GlobeNewswire
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

2024-02-22T13:00:00Z

BusinessWire
ORI Capital Raises $260 Million for Second Life Sciences Fund

2024-02-09T09:28:31-05:00

SEC
SC 13G/A Form - [Amend] Statement of acquisition of beneficial ownership by individuals - Orchard Therapeutics plc (0001748907) (Subject)

2024-02-08T19:01:40-05:00

SEC
SC 13G/A Form - [Amend] Statement of acquisition of beneficial ownership by individuals - Orchard Therapeutics plc (0001748907) (Subject)

2024-02-05T14:39:49-05:00

SEC
15-12G Form - Securities registration termination [Section 12(g)] - Orchard Therapeutics plc (0001748907) (Filer)

2024-02-05T12:00:03Z

GlobeNewswire
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

2024-02-02T12:00:28Z

GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium

2024-01-31T00:15:12-05:00

SEC
EFFECT Form - Notice of Effectiveness - Orchard Therapeutics plc (0001748907) (Filer)

2024-01-31T00:15:05-05:00

SEC
EFFECT Form - Notice of Effectiveness - Orchard Therapeutics plc (0001748907) (Filer)

2024-01-25T12:00:07Z

GlobeNewswire
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

2024-01-24T17:34:09-05:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Orchard Therapeutics plc (0001748907) (Issuer)

2024-01-24T17:29:38-05:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Orchard Therapeutics plc (0001748907) (Issuer)